What on earth is going on with the AstraZeneca share price?

The AstraZeneca share price has fallen 30% from its peak in August. Dr James Fox explains what’s going on with this FTSE 100 behemoth.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The AstraZeneca (LSE:AZN) share price just dipped below £100 per share. The stock has seriously underperformed in recent months, falling from above £130 in August.

So, let’s take a look at what’s being going on and explore whether investors are looking at an opportunity to buy stock in this British pharma giant.

Created with Highcharts 11.4.3AstraZeneca Plc PriceZoom1M3M6MYTD1Y5Y10YALLwww.fool.co.uk

China controversy

AstraZeneca’s shares slumped in early November following reports of an expanding insurance fraud investigation in China involving numerous senior executives.

Should you invest £1,000 in Aston Martin right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Aston Martin made the list?

See the 6 stocks

The probe, described as the largest insurance fraud case in China’s pharmaceutical sector in recent years, has implicated dozens of AstraZeneca staff, including China President Leon Wang.

The investigation has broadened to include various Chinese authorities, raising concerns about the company’s operations in its second-largest revenue market.

AstraZeneca has stated that it will cooperate with Chinese authorities, but hasn’t commented on the allegations.

Targets under scrutiny

The news has sparked worries about the stability of AstraZeneca’s sales in China, potentially impacting its goal of reaching $80bn in global revenue by 2030.

China contributed around 13% of total revenue in 2023 — AstraZeneca’s largest market is the US, followed by China, with Europe rounding out the top three.

Moreover, the country’s large population and expanding healthcare sector offer substantial opportunities for AstraZeneca’s oncology, biopharmaceuticals, and rare disease portfolios. It’s a central growth market as AstraZeneca looks to transform revenues, which stood at $45.8bn in 2023.

To achieve its revenue target, AstraZeneca plans to launch 20 new medicines by 2030, many of which have the potential to generate over $5bn in peak-year revenue. 

The company’s strategy involves developing treatments for at least half of all potential cancer types and pursuing alternatives to traditional treatments like chemotherapy and radiation.

The Trump effect

While the broad movement has been downwards, AstraZeneca stock pushed slightly higher after Donald Trump’s election victory. While I’ve read some mixed opinions, it appears his win is seen as modestly positive for the pharmaceutical industry, including AstraZeneca.

For one, his administration is likely to be more accommodating to mergers and acquisitions, potentially deprioritising the Inflation Reduction Act, and adopt a less aggressive stance on drug pricing.

However, uncertainty remains regarding FDA independence and the potential influence of anti-vaxxer Robert F. Kennedy Jr. on healthcare policy. In fact, as I write, a number of articles have just been published noting widespread concern about Kennedy.

The bottom line

It’s fair to say that there’s a lot going on which isn’t related to earnings or drug development. That’s going to make one of the most expensive stocks on the FTSE 100 pretty volatile.

However, pushing through the noise, the current forecasts and valuation data looks pretty strong. Sales are expected to rise to $52bn this year and earnings are forecasted to shoot up to £5.50 per share (up from £3.81).

In turn, this means the stock is trading around 23 times forward earnings, a figure that falls to 19.2 times and 17 times in 2025 and 2026 respectively.

I think it’s worthwhile being wary of the impact of this China investigation, while recognising that this could be a rare chance to pick up AstraZeneca stock on the cheap.

Personally, I’ve owned AstraZeneca shares for a while, but may hold back on buying more for the time being. Let’s see how things pan out.

Should you invest £1,000 in Aston Martin right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets.

And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Aston Martin made the list?

See the 6 stocks

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

James Fox has positions in AstraZeneca Plc. The Motley Fool UK has recommended AstraZeneca Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Like buying £1 for 51p

This seems ridiculous, but we almost never see shares looking this cheap. Yet this recent ‘Best Buy Now’ has a price/book ratio of 0.51. In plain English, this means that investors effectively get in on a business that holds £1 of assets for every 51p they invest!

Of course, this is the stock market where money is always at risk — these valuations can change and there are no guarantees. But some risks are a LOT more interesting than others, and at The Motley Fool we believe this company is amongst them.

What’s more, it currently boasts a stellar dividend yield of around 8.5%, and right now it’s possible for investors to jump aboard at near-historic lows. Want to get the name for yourself?

See the full investment case

More on Investing Articles

Investing Articles

Up 30% in weeks, does the BAE Systems share price still offer value?

The BAE Systems share price has been on a tear over the past couple of months. This writer sees limited…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Hunting for shares to buy as the market trembles? Remember this!

After a choppy week in global stock markets, our writer goes back to basics in his hunt for bargain shares…

Read more »

Investing Articles

3 simple principles to help build wealth in an ISA

As a new tax year opens up new ISA allowances for many investors, our writer shares a trio of things…

Read more »

Investing Articles

US trade tariffs: what they could mean for UK shares like Ashtead, Compass Group, and Experian

US trade tariffs continue to rock global markets, and the UK is no exception. Our writer considers how a new…

Read more »

Mindful young woman breathing out with closed eyes, calming down in stressful situation, working on computer in modern kitchen.
Dividend Shares

The Trump slump has smashed these FTSE 100 shares!

After a rough week for US and UK shares, investors have been shaken. But now these FTSE 100 stocks have…

Read more »

Investing Articles

£10,000 invested in Rolls-Royce shares 5 years ago is now worth…

Rolls-Royce shares have been on fire since April 2020. Part of this is the result of pandemic restrictions lifting, but…

Read more »

Young Asian woman with head in hands at her desk
Investing Articles

£10,000 invested in Tesla stock at its peak in 2024 is now worth…

Over the last few months, Tesla stock has lost nearly half its value. Here, Edward Sheldon explores a few takeaways…

Read more »

Investing Articles

Is the S&P 500 heading for an epic stock market crash?

Our writer shares his thoughts on a very crazy time for the S&P 500 and the wider stock market. How…

Read more »